Focus Areas & Addressing National Priorities
3 Focus Areas
Diagnostic & Remote
Laboratory Automation & Robotics
Addressing National Priorities
Characterised by chronic illnesses such as cancer, Alzheimer’s disease, and cardiovascular diseases, ageing has evolved to become one of the greatest risk factors. As our elderly population advances in years, they have become more susceptible to these diseases. Long-term care for the elderly has become one of the most daunting healthcare challenges.
Ageing population is one of the key issues in Singapore. The median age of Singapore residents has increased from 34.0 in 2000 to 41.8 in 2021¹. To address this problem, Singapore has taken a multifaceted, integrated and holistic approach to meet the needs of the elderly population. The approach will focus on home and community-based care which is preferred by many elderly and will optimise resources in Singapore for other purposes.
Aligned with the approach, our innovation efforts focus on tackling these challenges by working with companies whose intention is to delay these age-related diseases, and researching homecare robotic and monitoring systems where the elderly can participate in self-care. We look to co-innovating with partners in mobility assistance, fall prevention, rehabilitation care and wearable diagnostics where the quality of life for our elderly in Singapore can be significantly improved. Through securing healthy longevity and preventing chronic age-related diseases, we strive to build a future where our elderly can age confidently and gracefully in Singapore.
COVID-19 MedTech Innovations
Catalysing Translational R&D to Combat the Pandemic
When COVID-19 hit Singapore in 2019, a strong team of multi-disciplinary researchers from A*STAR came together to collaborate with the Diagnostic Development Hub (DxD), National Environment Agency (NEA), Ministry of Health (MOH), as well as industry partners such as Ramatex, KA Industrial, Sankei Eagle, Advanced MedTech and Sysmatic Global to support Singapore’s initiatives in battling the pandemic. Industry 4.0 technologies were mobilised to innovate and translate solutions to safeguard the health and well-being of our community as well as to assist our laboratory staff and healthcare workers in their work.
Solutions were developed:
Fast forward, Singapore has emerged stronger, more resilient and more ready to live with the virus in the midst. With plans to treat COVID-19 as an endemic, Singapore is seeking to pursue a strategy of “living with COVID-19”. Understanding that the journey will not be smooth and easy, Singapore will need to stay vigilant and adapt to any arising situation by preparing our healthcare system for more twists and turns or the emergence of a new disease. Disease X is not a matter of if, but when. Singapore will continue to stay nimble and learn as we strengthen our resilience against Disease X through the investment of R&D in science and technology. Our researchers remain committed to sustaining basic research and broadening research foundations with a key focus on biomedical science, health and human potential while collaborating with industry partners to co-innovate and co-translate these research into industrial solutions.
17 A*STAR researchers are recognised as the world's most influential scientific minds in 2022. Find out more about their work and what drives them to push the frontiers of scientific excellence!
A*STAR’s Highly Cited Researchers of 2022